Completed PHASE3 INTERVENTIONAL 2-arm NCT00636636

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia

Sponsor: Depomed

Conditions Neuralgia,Postherpetic

Interventions Gabapentin Extended Release tablets Placebo

Updated 7 times since 2017 Last updated: Feb 21, 2012 Started: Mar 31, 2008 Primary completion: Aug 31, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Neuralgia,Postherpetic and is currently completed. Depomed leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Depomed

Data source: Depomed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , All Over Russia, Russia , Ann Arbor, United States , Austin, United States , Birmingham, United States , Bismarck, United States , Buenos Aires, Argentina , Canton, United States , Cincinnati, United States , Colorado Springs, United States and 29 more locations